General Catalyst, a venture capital firm, led a $166m Series D funding round in Rakuten Medical, a global clinical-stage biotechnology company in pursuit of conquering cancer. Additional investors include Rakuten Group and SBI Group. "We are excited to partner with the world-class Rakuten Medical team as they pioneer breakthrough therapies and provide vital treatments to those battling cancer. We believe the extensibility of the Illuminox platform has the potential to redefine the way clinicians care for their patients. We are proud to lead Rakuten Medical's Series D funding as they expand into new therapies and indications," Paul Kwan, General Catalyst Managing Director.